ASSUAGE PHARMACEUTICALS, INC.

Biotech · Private

Small molecule antagonists of the α4β2 nicotinic acetylcholine receptor for smoking cessation

Grants
$1.2M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Novel selective alpha4beta2 nicotinic receptor antagonists for smoking cessation$491,318
Federal grantDepartment of Health and Human Services · Phase II · Novel selective alpha4beta2 nicotinic receptor antagonists for smoking cessation$5,000
Federal grantDepartment of Health and Human Services · Phase II · Novel selective alpha4beta2 nicotinic receptor antagonists for smoking cessation$500,849
Federal grantDepartment of Health and Human Services · Phase I · Discovery of alpha4beta2 Nicotinic Receptor Antagonists as Alcohol Abuse Medications$224,956
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3096NEUROLUX, INC.——
3097NEW YORK/R&D/CTR/TRANSLATIONAL MED/THER——
3098ImmPORT Therapeutics Inc dba Antigen Discovery Inc——
3099ASSUAGE PHARMACEUTICALS, INC.——
3100TUNITAS THERAPEUTICS, INC.——
3101KL50 THERAPEUTICS, LLC——
3102Medical Guidance Systems LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.